Verity Talbot

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13

Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1

Joseph Shaw, Ian L. Dale, Paul Hemsley et al. · SLAS DISCOVERY · 2018 · 49 citations · Full text

Pharmacy, Biochemistry, Molecular Biology +15

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance

M. Raymond V. Finlay, Peter Barton, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2021 · 32 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2024 · 27 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles

Elisabetta Leo, Jeffrey W. Johannes, Giuditta Illuzzi et al. · Cancer Research · 2018 · 23 citations

Medicine, Oncology, Pharmacology +16